CGRP vs Thymosin Beta-4

Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.

CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene, expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature, where it functions as a potent vasodilator and pain neuromodulator central to migraine pathophysiology. CGRP activates its receptor complex (CLR/RAMP1) to mediate vasodilation and nociceptive signal amplification; during migraine attacks, trigeminal activation releases CGRP at elevated plasma concentrations, and blockade of this pathway has been established as the primary validated pharmacological target for modern preventive migraine therapy. Phase 3 randomized controlled trials published in the New England Journal of Medicine and the Lancet — including the STRIVE trial (Goadsby et al. 2017) and a Phase 3b study in treatment-refractory patients — demonstrated that anti-CGRP monoclonal antibodies significantly reduced monthly migraine days versus placebo, validating the pathway and supporting FDA approval of erenumab, fremanezumab, and galcanezumab. CGRP itself is an endogenous neuropeptide and is not a therapeutic agent that is compounded or administered by providers; the FDA-approved interventions are monoclonal antibody and small-molecule receptor antagonists available by prescription, and exogenous CGRP peptide is exclusively a research tool compound used in vasodilatory and pain signaling pharmacology studies.

Sequesters G-actin monomers via its WH2 domain, regulating actin dynamics and cell migration. Upregulates metalloproteinases and growth factors for tissue remodeling. Promotes cardiomyocyte survival and angiogenesis post-injury.

Thymosin beta-4 (Tb4) is an endogenous 43-amino-acid protein ubiquitously expressed in mammalian tissues, best characterized for its role in G-actin sequestration, cell migration promotion, and tissue repair signaling across multiple organ systems. Tb4 exerts reparative effects by upregulating angiogenesis, modulating inflammation, and generating the anti-fibrotic tetrapeptide Ac-SDKP through enzymatic cleavage; preclinical models in cardiac, renal, and musculoskeletal tissue have demonstrated measurable regenerative outcomes following exogenous administration. Published literature supports anti-fibrotic activity in animal models of renal fibrosis and cardiovascular injury, and the Tb4-Ac-SDKP pathway has been characterized as a plausible target in fibrosis biology; however, clinical translation has been limited, with a Phase 2 cardiac repair trial that did not demonstrate efficacy sufficient to advance to Phase 3. Exogenous thymosin beta-4 has no FDA approval for any indication; it is available only as a research compound, and the substantial gap between preclinical findings and human clinical outcomes represents an important limitation of the current evidence base. Thymosin beta-4 vs TB-500 TB-500 is a commercial label used for synthetic thymosin beta-4 in the peptide research market. The underlying compound is the same 43-amino-acid sequence as endogenous Tb4; "TB-500" originated as a brand name from veterinary product contexts and has since become the predominant research market name for synthetic thymosin beta-4. When research suppliers, athletes, or forum communities reference TB-500, they are referring to synthetic Tb4 — the same compound profiled here. The TB-500 label is commonly associated with injectable research peptide use; the thymosin beta-4 label is associated with the biochemical and medical literature. Some suppliers sell "TB-4 Frag" (the Ac-SDKP tetrapeptide fragment), which is a distinct, smaller molecule derived from enzymatic cleavage of Tb4, not the full-length thymosin beta-4 protein. Thymosin beta-4 dosage in research contexts: Research protocols described in preclinical literature and anecdotal human use reports typically reference doses in the range of 2–5 mg per injection, administered subcutaneously or intramuscularly, with a loading phase of 2–4 injections per week followed by a maintenance phase of 1–2 injections per week. These dosage figures are derived from research compound use and veterinary contexts, not from FDA-approved human clinical protocols — no approved human dosing exists. The Phase 2 cardiac repair trial that administered intravenous Tb4 used significantly different dose and route parameters. Thymosin beta-4 is available only as a research compound; it is not FDA-approved for any human indication and is not available through licensed prescription channels.